Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
salmeterol · 3 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Salmeterol/fluticasone propionate 50/500mcg Diskus | DRUG | - |
| Salmeterol 50mcg/ Fluticasone Propionate 500mcg | DRUG | - |
| salmeterol | DRUG | - |
| tiotropium | DRUG | - |
| GSK233705 | DRUG | - |
Inclusion Criteria: * Established clinical history of chronic obstructive airways disease. * Must be current or ex-smokers with a smoking history of at least 10 pack-years (e.g. 20 cigarettes/day for 10 years or 10 cigarettes/day for 20 years). * Must have reduced lung function, defined as a Forced...
Salmeterol is a small molecule being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It has been evaluated in clinical trials involving patients with this condition, with studies conducted across multiple countries. The drug is in clinical development for respiratory use.
Salmeterol is developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research on this drug for the treatment of Chronic Obstructive Pulmonary Disease.
Salmeterol has completed Phase 3 clinical trials for Chronic Obstructive Pulmonary Disease. The drug is investigational and has been studied in clinical development programs. It has not been described as approved, and it remains in clinical research.
Salmeterol has been studied in three completed clinical trials. These include NCT00268177, which examined airway inflammation in COPD patients, and NCT00268216, which evaluated survival in subjects with COPD. A third trial, NCT00422604, assessed safety and efficacy of salmeterol in combination with another investigational drug.
Salmeterol is not the same as GSK233705. In one clinical trial, NCT00422604, salmeterol was studied in combination with GSK233705, which is a separate investigational compound. The trial compared this combination against other treatments in patients with COPD.